Table 1.
Baseline characteristics of patients
| Variables | All patients (n = 35) |
|---|---|
| Age, years, median (range) | 46 (27–67) |
| ≥50 | 15 (42.9%) |
| <50 | 20 (57.1%) |
| Sex, n (%) | |
| Male | 32 (91.4%) |
| Female | 3 (8.6%) |
| BMI, kg/m2, median (range) | 20.6 (17.3–28.8) |
| ≥24 | 10 (28.6%) |
| <24 | 25 (71.4%) |
| Etiology, n (%) | |
| Hepatitis B | 35 (100.00%) |
| ECOG performance status score, n (%) | |
| 0 | 16 (45.7%) |
| 1 | 18 (51.4%) |
| 2 | 1 (2.9%) |
| Child-Pugh score, n (%) | |
| 5 | 32 (91.4%) |
| 6 | 3 (8.6%) |
| ALBI grade, n (%) | |
| Grade 1 | 29 (82.9%) |
| Grade 2 | 6 (17.1%) |
| AFP, ng/mL, n (%) | |
| ≥400 | 19 (54.3%) |
| <400 | 16 (45.7%) |
| PIVKA-II, mAU/mL, median (range) | 8392.4 (42.0–75000.0) |
| Tumor size, cm, median (range) | 10.5 (4.7–18.9) |
| ≥10 | 21 (60.0%) |
| <10 | 14 (40.0%) |
| Venous tumor thrombus, n (%) | 31 (88.6%) |
| PVTT, n (%) | |
| Vp1 | 3 (8.6%) |
| Vp2 | 6 (17.1%) |
| Vp3 | 8 (22.9%) |
| Vp4 | 8 (22.9%) |
| Absent | 10 (28.6%) |
| IVCTT, n (%) | |
| Hepatic vein invasion | 8 (22.9%) |
| IVC invasion | 2 (5.7%) |
| Absent | 25 (71.4%) |
| Extrahepatic metastasis, n (%) | 5 (14.3%) |
BMI body mass index, ECOG Eastern Cooperative Oncology Group, ALBI albumin-bilirubin, AFP alpha-fetoprotein, PIVKA-II prothrombin in vitamin K absence II, PVTT portal vein tumor thrombosis, IVCTT inferior vena cava tumor thrombosis, IVC inferior vena cava